NICE has recommended Sleepio as an effective alternative to sleeping pills. The move would save the NHS money as well as reducing prescriptions of medicines such as zolpidem and zopiclone, which can be dependency-forming.
Sleepio is a six-week online programme designed by sleep experts based on cognitive and behavioural techniques. The app focuses on sleep restriction, stimulus control, cognitive tools and features a sleep hygiene review.
Up to 800,000 people in England could benefit from using the app, which utilises an AI algorithm to provide users with tailored digital cognitive behavioural therapy for insomnia (CBT-I).
Jeanette Kusel, acting director for MedTech and digital at NICE, explained: “Until now people with insomnia have been offered sleeping pills and taught about sleep hygiene, so our committee’s recommendation of Sleepio provides GPs and their patients with a new treatment option.”
The app provides a sleep test, weekly interactive CBT-I sessions and allows users to keep a diary tracking their sleeping patterns. Meanwhile, CBT-I sessions focus on identifying thoughts, feelings and behaviours that contribute to the symptoms of insomnia.
Cognitive interventions aim to improve the way a person thinks about sleep and the behavioural interventions aspire to a healthy sleep routine.
Kusel continued: “Our rigorous, transparent and evidence-based analysis has found that Sleepio is cost saving for the NHS compared with usual treatments in primary care. It will also reduce people with insomnia’s reliance on dependence forming drugs such as zolpidem and zopiclone.”
“This is a good example of where a digital health technology can help the NHS. The evidence has shown using Sleepio reduces the number of GP appointments people with insomnia need and will also cut the number of prescriptions for sleeping pills delivered by pharmacists,” she added.
By Ana Ovey
Source: pharmatimes.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
